MX351599B - Polimeros cationicos con base en glucogeno. - Google Patents

Polimeros cationicos con base en glucogeno.

Info

Publication number
MX351599B
MX351599B MX2014010698A MX2014010698A MX351599B MX 351599 B MX351599 B MX 351599B MX 2014010698 A MX2014010698 A MX 2014010698A MX 2014010698 A MX2014010698 A MX 2014010698A MX 351599 B MX351599 B MX 351599B
Authority
MX
Mexico
Prior art keywords
cationic polymers
glycogen
based cationic
complexes
anionic compounds
Prior art date
Application number
MX2014010698A
Other languages
English (en)
Other versions
MX2014010698A (es
Inventor
Cazzolla Nicola
Russo Vincenzo
Liberati Elisa
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2014010698A publication Critical patent/MX2014010698A/es
Publication of MX351599B publication Critical patent/MX351599B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/18—Reserve carbohydrates, e.g. glycogen, inulin, laminarin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se refiere a polímeros catiónicos con base en glucógeno, a complejos de dichos polímeros catiónicos con compuestos aniónicos, a composiciones farmacéuticas que comprenden dichos complejos, y al uso de dichos complejos para entregar o transfectar dichos compuestos aniónicos para un blanco farmacológico específico, tal como, por ejemplo un órgano, un tejido o una célula.
MX2014010698A 2012-03-15 2013-02-21 Polimeros cationicos con base en glucogeno. MX351599B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12159710 2012-03-15
PCT/EP2013/053422 WO2013135471A1 (en) 2012-03-15 2013-02-21 Glycogen-based cationic polymers

Publications (2)

Publication Number Publication Date
MX2014010698A MX2014010698A (es) 2015-03-10
MX351599B true MX351599B (es) 2017-10-20

Family

ID=47739282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010698A MX351599B (es) 2012-03-15 2013-02-21 Polimeros cationicos con base en glucogeno.

Country Status (29)

Country Link
US (1) US9717801B2 (es)
EP (1) EP2825565B1 (es)
JP (1) JP6247234B2 (es)
KR (1) KR101997018B1 (es)
CN (2) CN104080812B (es)
AR (1) AR090307A1 (es)
AU (1) AU2013231561B2 (es)
BR (1) BR112014018617A8 (es)
CA (1) CA2859273C (es)
CY (1) CY1121829T1 (es)
DK (1) DK2825565T3 (es)
EA (1) EA032479B1 (es)
ES (1) ES2732216T3 (es)
GE (1) GEP201606581B (es)
HR (1) HRP20191114T1 (es)
HU (1) HUE045049T2 (es)
IL (1) IL233823B (es)
LT (1) LT2825565T (es)
ME (1) ME03429B (es)
MX (1) MX351599B (es)
PL (1) PL2825565T3 (es)
PT (1) PT2825565T (es)
RS (1) RS58985B1 (es)
SG (2) SG11201403816YA (es)
SI (1) SI2825565T1 (es)
SM (1) SMT201900342T1 (es)
TR (1) TR201909387T4 (es)
UA (1) UA115135C2 (es)
WO (1) WO2013135471A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095937A1 (es) 2013-04-05 2015-11-25 Acraf Potenciador de la solubilidad en agua a base de glucógeno
US10172946B2 (en) 2013-04-26 2019-01-08 Mirexus Biotechnologies Inc. Monodisperse glycogen and phytoglycogen nanoparticles and use thereof as additives in cosmetics, pharmaceuticals, and food products
EP3241903A4 (en) * 2014-12-29 2018-07-04 Bonac Corporation Composition containing nucleic acid molecule stably
CN104558246B (zh) * 2015-01-20 2017-03-01 武汉理工大学 一种叶酸/生物素修饰的壳聚糖材料及其制备方法
DE102015205088C5 (de) * 2015-03-20 2024-09-26 Kuka Deutschland Gmbh Verfahren zum Ermitteln eines Kalibrierungsparameters eines Fahrzeuges sowie Fahrzeug hierzu
JP6872782B2 (ja) * 2016-03-08 2021-05-19 国立大学法人京都大学 カチオン性グルカンナノスフェア、複合体、核酸導入剤及びがん治療剤
CA3020772A1 (en) * 2016-04-14 2017-10-19 Mirexus Biotechnologies Inc. Anti-infective compositions comprising phytoglycogen nanoparticles
US20190117681A1 (en) * 2016-05-04 2019-04-25 Mirexus Biotechnologies Inc. Glycogen and phytoglycogen nanoparticles as immunosuppressive compounds, and compositions and methods of use thereof
CN105949344B (zh) * 2016-05-13 2019-05-17 中山大学 一种阳离子超支化多糖衍生物及其在增强血卟啉类光敏剂对肿瘤细胞光毒性方面的应用
US12029790B2 (en) 2017-07-31 2024-07-09 Ohio State Innovation Foundation Biomimetic nanomaterials and uses thereof
US11384161B2 (en) 2018-01-11 2022-07-12 Virginia Tech Intellectual Properties, Inc. Amphiphilic polysaccharides, polysaccharide-based hydrogels, and methods of manufacture
CN116178587B (zh) * 2023-02-28 2025-04-11 江南大学 一种季铵盐化糖原、复合抗菌水凝胶及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
IT1255488B (it) 1992-08-04 1995-11-06 Angelini Francesco Ist Ricerca Polisaccaridi del glicogeno
US7144713B1 (en) 1995-10-02 2006-12-05 Emd Biosciences, Inc. Method for precipitating nucleic acid with visible carrier
GB9600272D0 (en) 1996-01-06 1996-03-06 Univ Nottingham Polymers
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
US20030147958A1 (en) 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
US20030186916A1 (en) 2002-03-12 2003-10-02 Lei Yu Vector for transfection of eukaryotic cells
US20090117657A1 (en) * 2004-03-31 2009-05-07 Medgel Corporation Preparation For Transferring Nucleic Acid Into Cell
US8108158B2 (en) 2005-09-28 2012-01-31 Adrian H. Hetzel Electro-hydraulic timed angle controlled joint simulation torque calibration, certification and analysis device
UA97559C2 (uk) * 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
CN101235098A (zh) * 2008-01-09 2008-08-06 浙江大学 功能性植物多糖的修饰方法
EP2366009B1 (en) * 2008-12-22 2012-10-24 Unilever PLC Laundry compositions
ES2393529T3 (es) * 2008-12-22 2012-12-26 Unilever Nv Composiciones de lavandería
EP2428578B1 (en) * 2009-05-08 2016-03-23 Ezaki Glico Co., Ltd. Glucuronic acid-containing glucan, process for production of same, and use of same
EP2275085A1 (en) * 2009-07-07 2011-01-19 University of Rostock Biodegradable copolymer suitable for delivering nucleic acid materials into cells
CN102068698A (zh) * 2009-11-24 2011-05-25 深圳先进技术研究院 纳米疫苗及其制备方法

Also Published As

Publication number Publication date
US20140378532A1 (en) 2014-12-25
EP2825565A1 (en) 2015-01-21
IL233823B (en) 2018-05-31
JP2015510020A (ja) 2015-04-02
KR20150006414A (ko) 2015-01-16
CN107236052B (zh) 2019-09-24
DK2825565T3 (da) 2019-06-24
HK1203984A1 (en) 2015-11-06
HUE045049T2 (hu) 2019-12-30
RS58985B1 (sr) 2019-08-30
AU2013231561A1 (en) 2014-07-10
CA2859273C (en) 2020-04-14
SG11201403816YA (en) 2014-08-28
SI2825565T1 (sl) 2019-08-30
EA201491613A1 (ru) 2014-12-30
KR101997018B1 (ko) 2019-07-05
BR112014018617A8 (pt) 2017-07-11
PT2825565T (pt) 2019-07-10
TR201909387T4 (tr) 2019-07-22
PL2825565T3 (pl) 2019-10-31
EA032479B1 (ru) 2019-06-28
AR090307A1 (es) 2014-11-05
IL233823A0 (en) 2014-09-30
CN104080812B (zh) 2017-06-27
ES2732216T3 (es) 2019-11-21
SMT201900342T1 (it) 2019-07-11
UA115135C2 (uk) 2017-09-25
JP6247234B2 (ja) 2017-12-13
HRP20191114T1 (hr) 2019-09-20
CN104080812A (zh) 2014-10-01
BR112014018617A2 (es) 2017-06-20
CA2859273A1 (en) 2013-09-19
MX2014010698A (es) 2015-03-10
CY1121829T1 (el) 2020-07-31
SG10201607577QA (en) 2016-11-29
GEP201606581B (en) 2016-11-25
WO2013135471A1 (en) 2013-09-19
LT2825565T (lt) 2019-07-10
EP2825565B1 (en) 2019-04-03
AU2013231561B2 (en) 2017-06-08
CN107236052A (zh) 2017-10-10
ME03429B (me) 2020-01-20
US9717801B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
MX351599B (es) Polimeros cationicos con base en glucogeno.
JOP20180102A1 (ar) مركب صيدلاني
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
IN2015DN03029A (es)
MX359291B (es) Adn libre de celulas como objetivo terapeutico para la infertilidad femenina y marcador de diagnostico.
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
TN2014000319A1 (en) Imidazopyrrolidinone compounds
MX352245B (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
MX2016008448A (es) Conjugados de var2csa-farmaco.
BR112014025041B8 (pt) Composição farmacêutica
PH12014502032A1 (en) Treatment of brain cancer
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EP4331622A3 (en) Integrin binding peptides and uses thereof
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
IL238931A0 (en) Production methods for (1s,4s,5s)-4-bromo-6-oxabicyclo)[3,2,1]octane-7-one
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
GEP201706708B (en) Isoxazolidine derivatives
IN2015DN02660A (es)
IN2012DE00937A (es)
WO2014009245A3 (en) Novel drug target indentification methods

Legal Events

Date Code Title Description
FG Grant or registration